Vident Investment Advisory’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Vident Investment Advisory’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,457	Closed	-$229K	–	1047
2020 Q4	$229K	Hold	12,457	–	–	0.01%	858
2020 Q3	$228K	Buy	12,457 +1,975	+19%	+$33.2K	0.01%	811
2020 Q2	$157K	Sell	10,482 -2,800	-21%	-$40K	0.01%	822
2020 Q1	$210K	Sell	13,282 -4,197	-24%	-$67.8K	0.01%	747
2019 Q4	$284K	Buy	17,479 +5,106	+41%	+$85.2K	0.02%	648
2019 Q3	$184K	Buy	+12,373	New	+$167K	0.02%	446

Vident Investment Advisory's CBMG Position: Q1 2021 in Review

Vident Investment Advisory sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 12,457 shares — an estimated $229K sold.

Vident Investment Advisory first reported a position in CBMG in Q3 2019 and held it in 6 quarters. The position peaked at $284K in Q4 2019. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

Vident Investment Advisory reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
Vident Investment Advisory sold 12,457 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $229K.
Vident Investment Advisory first reported a position in Cellular Biomedicine Group, Inc. in Q3 2019 and held it in 6 quarters.
Vident Investment Advisory's Cellular Biomedicine Group, Inc. position peaked at $284K in Q4 2019.
0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Vident Investment Advisory's 13F filing for Q1 2021, filed 14 May 2021.